Mayne protocol 18-ICH-001: A Phase 2 Randomized, Multicenter, Doubleblind, Vehicle Controlled, 12 Week, Safety, Efficacy & Systemic Exposure Study Followed by a 12 Week Open-label Extension of CD5789 in Adults and Adolescents With Autosomal Recessive Ichthyosis With Lamellar Scale – CURRENTLY ENROLLING

• A phase II study for patients with a genetic condition called lamellar ichthyosis.

Trifarotene cream

• We are looking for patients with ichthyosis with lamellar scale to participate in a trial investigating trifarotene cream (topical retinoid). 2/3 chance of receiving the medication for the first 3 months, after that all patients will receive open-label trifarotene. Enrolling now!